Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia
- PMID: 8014285
- DOI: 10.1007/BF01704699
Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia
Abstract
Objective: to investigate the epidemiology of infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia (VAP).
Design: prospective clinical study.
Setting: a medical-surgical ICU in a university hospital.
Patients: we followed-up 568 mechanically ventilated patients and 83 episodes of VAP with etiologic diagnosis in 72 patients were retained for analysis.
Results: Ps. aeruginosa was isolated in 22 (26.5%) episodes in 18 patients. Of these episodes 7 were directly responsible for death. Using logistic regression analysis, the risk of VAP due to Ps. aeruginosa was increased in patients with chronic obstructive pulmonary disease (relative risk (RR) = 29.9, 95% confidence interval (CI) = 4.86-184.53), a mechanical ventilation period longer than 8 days (RR = 8.1, 95% CI = 1.01-65.40) and prior use of antibiotics (RR = 5.5, 95% CI = 0.88-35.01).
Conclusions: patients with VAP and these factors have a greater risk of infection by Ps. aeruginosa and empirical therapy for these episodes should include anti-pseudomonal activity until etiologic diagnosis is established.
Similar articles
-
Prospective study of nosocomial colonization and infection due to Pseudomonas aeruginosa in mechanically ventilated patients.Intensive Care Med. 2001 Mar;27(3):503-12. doi: 10.1007/s001340100870. Intensive Care Med. 2001. PMID: 11355118
-
Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study.Trials. 2017 Jan 23;18(1):37. doi: 10.1186/s13063-017-1780-3. Trials. 2017. PMID: 28114979 Free PMC article. Clinical Trial.
-
Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia.Am J Respir Crit Care Med. 2001 May;163(6):1371-5. doi: 10.1164/ajrccm.163.6.2007020. Am J Respir Crit Care Med. 2001. PMID: 11371403
-
Ventilator-associated pneumonia.Semin Respir Crit Care Med. 2014 Aug;35(4):469-81. doi: 10.1055/s-0034-1384752. Epub 2014 Aug 11. Semin Respir Crit Care Med. 2014. PMID: 25111643 Review.
-
Nosocomial pneumonia in the intensive care unit: controversies and dilemmas.J Intensive Care Med. 2003 Jul-Aug;18(4):175-88. doi: 10.1177/0885066603254249. J Intensive Care Med. 2003. PMID: 15035764 Review.
Cited by
-
COPD patients with ventilator-associated pneumonia: implications for management.Eur J Clin Microbiol Infect Dis. 2015 Dec;34(12):2403-11. doi: 10.1007/s10096-015-2495-6. Epub 2015 Sep 25. Eur J Clin Microbiol Infect Dis. 2015. PMID: 26407622
-
Management of ventilator-associated pneumonia in a multidisciplinary intensive care unit: does trauma make a difference?Intensive Care Med. 2007 Aug;33(8):1387-95. doi: 10.1007/s00134-007-0729-5. Epub 2007 Jun 12. Intensive Care Med. 2007. PMID: 17563873
-
Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy".Intensive Care Med. 2003 Jun;29(6):876-883. doi: 10.1007/s00134-003-1715-1. Epub 2003 Apr 2. Intensive Care Med. 2003. PMID: 12677369 Review.
-
Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial.Crit Care. 2020 Mar 4;24(1):74. doi: 10.1186/s13054-020-2792-z. Crit Care. 2020. PMID: 32131866 Free PMC article. Clinical Trial.
-
Anti-Pseudomonas aeruginosa Vaccines and Therapies: An Assessment of Clinical Trials.Microorganisms. 2023 Mar 31;11(4):916. doi: 10.3390/microorganisms11040916. Microorganisms. 2023. PMID: 37110338 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Medical